Perspective Therapeutics Inc (CATX)
2.645
-0.06
(-2.40%)
USD |
NYAM |
Oct 09, 16:00
2.645
0.00 (0.00%)
After-Hours: 17:44
Perspective Therapeutics Net Income (Quarterly) : -26.98M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -26.98M |
| March 31, 2026 | -26.19M |
| December 31, 2025 | -37.49M |
| September 30, 2025 | -25.97M |
| June 30, 2025 | -22.00M |
| March 31, 2025 | -18.18M |
| December 31, 2024 | -40.11M |
| September 30, 2024 | -15.12M |
| June 30, 2024 | -11.28M |
| March 31, 2024 | -11.82M |
| September 30, 2023 | -9.572M |
| June 30, 2023 | -9.486M |
| March 31, 2023 | 1.095M |
| June 30, 2022 | -2.078M |
| March 31, 2022 | -1.347M |
| December 31, 2021 | -1.604M |
| September 30, 2021 | -2.243M |
| June 30, 2021 | -1.061M |
| March 31, 2021 | -0.745M |
| December 31, 2020 | -0.868M |
| September 30, 2020 | -0.713M |
| June 30, 2020 | -1.188M |
| March 31, 2020 | -0.545M |
| December 31, 2019 | -0.897M |
| September 30, 2019 | -0.816M |
| Date | Value |
|---|---|
| June 30, 2019 | -1.095M |
| March 31, 2019 | -1.127M |
| December 31, 2018 | -1.414M |
| September 30, 2018 | -1.508M |
| June 30, 2018 | -2.358M |
| March 31, 2018 | -1.332M |
| December 31, 2017 | -1.463M |
| September 30, 2017 | -1.546M |
| June 30, 2017 | -1.854M |
| March 31, 2017 | -1.36M |
| December 31, 2016 | -1.45M |
| September 30, 2016 | -1.498M |
| June 30, 2016 | -1.185M |
| March 31, 2016 | -1.195M |
| December 31, 2015 | -1.312M |
| September 30, 2015 | -1.019M |
| June 30, 2015 | -1.035M |
| March 31, 2015 | -0.9536M |
| December 31, 2014 | -0.907M |
| September 30, 2014 | -0.7859M |
| June 30, 2014 | -1.678M |
| March 31, 2014 | -2.083M |
| December 31, 2013 | -0.927M |
| September 30, 2013 | -1.271M |
| June 30, 2013 | -0.9936M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Biogen, Inc. | 97.50M |
| Rigel Pharmaceuticals, Inc. | 17.29M |
| Enanta Pharmaceuticals, Inc. | -19.50M |
| Insight Molecular Diagnostics, Inc. | -11.26M |
| BridgeBio Pharma, Inc. | -155.89M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.081M |
| Total Expenses (Quarterly) | 27.06M |
| EPS Diluted (Quarterly) | -0.222 |
| Enterprise Value | 76.26M |
| Gross Profit Margin (Quarterly) | -1.31K% |
| Profit Margin (Quarterly) | -33.31K% |
| Earnings Yield | -50.23% |
| Normalized Earnings Yield | -46.67 |